Apyx Medical Q2 revenue up 32% to $13.6M, net loss narrows 82% to $1.0M, reaffirms FY2023 guide

Apyx Medical Corp

2023-Q2 EPS reported -$0.13 revenue$25,711,000

Advanced Energy revenue rose 40% YoY to $11.7M; OEM revenue fell 4% to $1.8M.
Net loss improved to $1.0M ($0.03 loss per share) from $5.4M in Q2 2022.
Adjusted EBITDA loss decreased 52% to $1.6M; gross margin expanded to 68.4%.
FY2023 outlook reaffirmed: total revenue $59-62M, Advanced Energy $51-54M, net loss ~$10.5M.
Completed sale-leaseback of Clearwater facility, netting ~$6.6M; received two FDA 510(k) clearances in Q2.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Apyx Medical Corp reported second quarter ended June 30, 2023 results: revenue $13.6 million, net income Net loss attributable to stockholders of $1.0 million. Guidance reaffirmed.

Period: second quarter ended June 30, 2023
Revenue: $13.6 million
Net income: Net loss attributable to stockholders of $1.0 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

second quarter ended June 30, 2023, and reaffirms financial expectations for the full year ending December 31, 2023. Second Quarter 2023 Financial Summary : • Total revenue of $13.6 million, up 32% year-over-year. ◦ Advanced Energy revenue of $11.7 million, up 40% year-over-year. ◦ OEM revenue of $1.8 million, down 4% year-over-year. • Net loss attributable to

View on SEC.gov

Browse all earnings releases →

Apyx Medical Corp filing history →

Source: SEC EDGAR

accession 0000719135-23-000045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.